The FDA granted approval to Genentech’s Phesgo, a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) with hyaluronidase, administered by subcutaneous injection in combination with IV chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.
Phesgo is available in one single-dose vial. Administration can take approximately eight minutes for the initial loading dose and approximately five minutes for each subsequent maintenance dose.